-
1
-
-
64549104914
-
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
-
for the ATRIA Study Investigators
-
Go, A. S., et al. for the ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 119, 1363-1369 (2009).
-
(2009)
Circulation
, vol.119
, pp. 1363-1369
-
-
Go, A.S.1
-
2
-
-
77952988390
-
Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)
-
Soliman, E. Z., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J. 159, 1102-1107 (2010).
-
(2010)
Am. Heart J.
, vol.159
, pp. 1102-1107
-
-
Soliman, E.Z.1
-
3
-
-
79953769563
-
Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
-
Baber, U., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ. Arrhythm. Electrophysiol. 4, 26-32 (2011).
-
(2011)
Circ. Arrhythm. Electrophysiol.
, vol.4
, pp. 26-32
-
-
Baber, U.1
-
5
-
-
84857438475
-
New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation
-
Ansell, J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 125, 165-170 (2012).
-
(2012)
Circulation
, vol.125
, pp. 165-170
-
-
Ansell, J.1
-
6
-
-
84855402737
-
Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism
-
Granger, C. B. & Armaganijan, L. V. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 125, 159-164 (2012).
-
(2012)
Circulation
, vol.125
, pp. 159-164
-
-
Granger, C.B.1
Armaganijan, L.V.2
-
7
-
-
65649145705
-
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
-
The ACTIVE Investigators
-
The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066-2078 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 2066-2078
-
-
-
8
-
-
33744945247
-
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial
-
Connolly, S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
-
(2006)
Lancet
, vol.367
, pp. 1903-1912
-
-
Connolly, S.1
-
9
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly, S. J., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
-
10
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
for the AVERROES Steering Committee and Investigators
-
Connolly, S. J., et al. for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 806-817
-
-
Connolly, S.J.1
-
11
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel, M. R., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
-
12
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
for the ARISTOTLE Committees and Investigators
-
Granger, C. B., et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
-
13
-
-
0345414673
-
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial
-
Executive Steering Committee on behalf of the SPORTIF III Investigators
-
Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
-
(2003)
Lancet
, vol.362
, pp. 1691-1698
-
-
-
14
-
-
13444309949
-
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial
-
SPORTIF Executive Steering Committee for the SPORTIF V Investigators
-
SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690-698 (2005).
-
(2005)
JAMA
, vol.293
, pp. 690-698
-
-
-
15
-
-
77957932391
-
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF TIMI 48)
-
Ruff, C. T., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF TIMI 48). Am. Heart J. 160, 635-641 (2010).
-
(2010)
Am. Heart J.
, vol.160
, pp. 635-641
-
-
Ruff, C.T.1
-
16
-
-
84859971855
-
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
-
Kaatz, S., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 87 (Suppl. 1), S141-S145 (2012).
-
(2012)
Am. J. Hematol.
, vol.87
, Issue.SUPPL. 1
-
-
Kaatz, S.1
-
17
-
-
84861616750
-
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE LY trial
-
Hart, R. G., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE LY trial. Stroke 43, 1511-1517 (2012).
-
(2012)
Stroke
, vol.43
, pp. 1511-1517
-
-
Hart, R.G.1
-
18
-
-
84857853180
-
Bleeding risk with dabigatran in the frail elderly
-
Harper, P., Young, L. & Merriman, E. Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366, 864-866 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 864-866
-
-
Harper, P.1
Young, L.2
Merriman, E.3
-
20
-
-
57149140461
-
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
-
on behalf of the ACTIVE W Investigators
-
Connolly, S. J., et al. on behalf of the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118, 2029-2037 (2008).
-
(2008)
Circulation
, vol.118
, pp. 2029-2037
-
-
Connolly, S.J.1
-
21
-
-
33847006936
-
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and v
-
White, H. D., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 167, 239-245 (2007).
-
(2007)
Arch. Intern. Med.
, vol.167
, pp. 239-245
-
-
White, H.D.1
-
22
-
-
15844410955
-
Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: A record linkage study in a large British population
-
Jones, M., et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91, 472-477 (2005).
-
(2005)
Heart
, vol.91
, pp. 472-477
-
-
Jones, M.1
-
23
-
-
65449163045
-
Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States
-
Baker, W. L., Cios, D. A., Sander, S. D. & Coleman, C. I. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15, 244-252 (2009).
-
(2009)
J. Manag. Care Pharm.
, vol.15
, pp. 244-252
-
-
Baker, W.L.1
Cios, D.A.2
Sander, S.D.3
Coleman, C.I.4
-
24
-
-
52449129321
-
Warfarin for atrial fibrillation in community-based practise
-
Rose, A. J., Ozonoff, A., Henault, L. E. & Hylek, E. M. Warfarin for atrial fibrillation in community-based practise. J. Thromb. Haemost. 6, 1647-1654 (2008).
-
(2008)
J. Thromb. Haemost.
, vol.6
, pp. 1647-1654
-
-
Rose, A.J.1
Ozonoff, A.2
Henault, L.E.3
Hylek, E.M.4
-
25
-
-
80054071757
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
-
Fox, K. A., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32, 2387-2394 (2011).
-
(2011)
Eur. Heart J.
, vol.32
, pp. 2387-2394
-
-
Fox, K.A.1
-
26
-
-
34548509436
-
Atrial fibrillation in haemodialysis patients: Do guidelines for anticoagulation apply?
-
To, A. C., Yehia, M. & Collins, J. F. Atrial fibrillation in haemodialysis patients: do guidelines for anticoagulation apply? Nephrology (Carlton) 12, 441-447 (2007).
-
(2007)
Nephrology (Carlton)
, vol.12
, pp. 441-447
-
-
To, A.C.1
Yehia, M.2
Collins, J.F.3
-
27
-
-
65249178935
-
Kidney function influences warfarin responsiveness and hemorrhagic complications
-
Limdi, N. A., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 20, 912-921 (2009).
-
(2009)
J. Am. Soc. Nephrol.
, vol.20
, pp. 912-921
-
-
Limdi, N.A.1
-
28
-
-
0036707888
-
Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial
-
Crowther, M. A., et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J. Am. Soc. Nephrol. 13, 2331-2337 (2002).
-
(2002)
J. Am. Soc. Nephrol.
, vol.13
, pp. 2331-2337
-
-
Crowther, M.A.1
-
29
-
-
84879799019
-
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease
-
in press
-
Eikelboom, J. W., et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J. Stroke Cerebrovasc. Dis. (in press).
-
J. Stroke Cerebrovasc. Dis.
-
-
Eikelboom, J.W.1
-
30
-
-
80655139710
-
Warfarin in atrial fibrillation patients with moderate chronic kidney disease
-
Hart, R. G., Pearce, L. A., Asinger, R. W. & Herzog, C. A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 2599-2604 (2011).
-
(2011)
Clin. J. Am. Soc. Nephrol.
, vol.6
, pp. 2599-2604
-
-
Hart, R.G.1
Pearce, L.A.2
Asinger, R.W.3
Herzog, C.A.4
-
31
-
-
79952316518
-
Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation
-
Nakagawa, K., et al. Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am. J. Cardiol. 107, 912-916 (2011).
-
(2011)
Am. J. Cardiol.
, vol.107
, pp. 912-916
-
-
Nakagawa, K.1
-
32
-
-
0035854054
-
Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation
-
Gage, B. F., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
-
(2001)
JAMA
, vol.285
, pp. 2864-2870
-
-
Gage, B.F.1
-
33
-
-
34548455445
-
Independent predictors of stroke in patients with atrial fibrillation: A systematic review
-
Stroke Risk in Atrial Fibrillation Working Group
-
Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546-554 (2007).
-
(2007)
Neurology
, vol.69
, pp. 546-554
-
-
-
34
-
-
78650878679
-
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score
-
Lip, G. Y., Frison, L., Halperin, J. L. & Lane, D. A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 57, 173-180 (2011).
-
(2011)
J. Am. Coll. Cardiol.
, vol.57
, pp. 173-180
-
-
Lip, G.Y.1
Frison, L.2
Halperin, J.L.3
Lane, D.A.4
-
35
-
-
33751255101
-
Development of a contemporary bleeding risk model for elderly warfarin recipients
-
Shireman, T. I., et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 130, 1390-1396 (2006).
-
(2006)
Chest
, vol.130
, pp. 1390-1396
-
-
Shireman, T.I.1
-
36
-
-
80052094564
-
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
-
Fang, M. C., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 58, 395-401 (2011).
-
(2011)
J. Am. Coll. Cardiol.
, vol.58
, pp. 395-401
-
-
Fang, M.C.1
-
37
-
-
33344461585
-
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
-
Gage, B. F., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151, 713-719 (2006).
-
(2006)
Am. Heart J.
, vol.151
, pp. 713-719
-
-
Gage, B.F.1
-
38
-
-
80055079237
-
Risk of bleeding with oral anticoagulants: An updated systematic review and performance analysis of clinical prediction rules
-
Loewen, P. & Dahri, K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann. Hematol. 90, 1191-1200 (2011).
-
(2011)
Ann. Hematol.
, vol.90
, pp. 1191-1200
-
-
Loewen, P.1
Dahri, K.2
-
39
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
40
-
-
84879799310
-
-
U. S. Food and Drug Administration and Dabigatran Briefing Document [online]
-
U. S. Food and Drug Administration. Dabigatran Briefing Document [online], http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm226009.pdf (2010).
-
(2010)
-
-
-
41
-
-
79958126202
-
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
-
Eikelboom, J. W., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 123, 2363-2372 (2011).
-
(2011)
Circulation
, vol.123
, pp. 2363-2372
-
-
Eikelboom, J.W.1
-
43
-
-
72449133295
-
-
U. S. Food and Drug Administration
-
U. S. Food and Drug Administration. FDA approved drug products: Xarelto [online], http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Overview&DrugName=XARELTO (2011).
-
(2011)
FDA Approved Drug Products: Xarelto [Online]
-
-
-
44
-
-
84879798911
-
-
Health Canada. Drugs and Health Products: Pradax [online]
-
Health Canada. Drugs and Health Products: Pradax [online], http://webprod3.hc-sc.gc.ca/noc-ac/info.do?lang=eng&no=11817 (2010).
-
(2010)
-
-
-
45
-
-
84879796711
-
-
Health Canada. Drugs Health Products: Xarelto [online]
-
Health Canada. Drugs and Health Products: Xarelto [online], http://webprod3.hc-sc.gc.ca/noc-ac/info.do?lang=eng&no=12966 (2012).
-
(2012)
-
-
-
46
-
-
84879795107
-
-
European Medicines Agency. Product information: Pradaxa [online]
-
European Medicines Agency. Product information: Pradaxa [online], http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf (2012).
-
(2012)
-
-
-
47
-
-
84879794134
-
-
European Medicines Agency. Product information: Xarelto [online]
-
European Medicines Agency. Product information: Xarelto [online], http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000944/WC500057108.pdf (2012).
-
(2012)
-
-
-
48
-
-
77949421739
-
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study
-
Stangier, J., Rathgen, K., Stähle, H. & Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49, 259-268 (2010).
-
(2010)
Clin. Pharmacokinet.
, vol.49
, pp. 259-268
-
-
Stangier, J.1
Rathgen, K.2
Stähle, H.3
Mazur, D.4
-
49
-
-
84858595913
-
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control
-
Skanes, A. C., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28, 125-136 (2012).
-
(2012)
Can. J. Cardiol.
, vol.28
, pp. 125-136
-
-
Skanes, A.C.1
-
50
-
-
84857759555
-
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
-
Warkentin, T. E., et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119, 2172-2174 (2012).
-
(2012)
Blood
, vol.119
, pp. 2172-2174
-
-
Warkentin, T.E.1
-
51
-
-
77953168824
-
Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn, J., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
-
(2010)
Thromb. Haemost.
, vol.103
, pp. 1116-1127
-
-
Van Ryn, J.1
-
52
-
-
70349908012
-
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation
-
Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223-2233 (2009).
-
(2009)
J. Am. Soc. Nephrol.
, vol.20
, pp. 2223-2233
-
-
Chan, K.E.1
Lazarus, J.M.2
Thadhani, R.3
Hakim, R.M.4
-
53
-
-
27144535900
-
Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients
-
Genovesi, S., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am. J. Kidney Dis. 46, 897-902 (2005).
-
(2005)
Am. J. Kidney Dis.
, vol.46
, pp. 897-902
-
-
Genovesi, S.1
-
54
-
-
84857095835
-
The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients
-
Wetmore, J. B., et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 81, 469-476 (2012).
-
(2012)
Kidney Int.
, vol.81
, pp. 469-476
-
-
Wetmore, J.B.1
-
55
-
-
0141794137
-
Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis
-
Vázquez, E., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am. J. Cardiol. 92, 868-871 (2003).
-
(2003)
Am. J. Cardiol.
, vol.92
, pp. 868-871
-
-
Vázquez, E.1
-
56
-
-
77956897768
-
Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy
-
Wizemann, V., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 77, 1098-1106 (2010).
-
(2010)
Kidney Int
, vol.77
, pp. 1098-1106
-
-
Wizemann, V.1
-
57
-
-
38149077292
-
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients
-
Genovesi, S., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am. J. Kidney Dis. 51, 255-262 (2008).
-
(2008)
Am. J. Kidney Dis.
, vol.51
, pp. 255-262
-
-
Genovesi, S.1
-
58
-
-
80755152863
-
Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation
-
Winkelmayer, W. C., Liu, J., Setoguchi, S. & Choudry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation. Clin. J. Am. Soc. Nephrol. 6, 2662-2668 (2011).
-
(2011)
Clin. J. Am. Soc. Nephrol.
, vol.6
, pp. 2662-2668
-
-
Winkelmayer, W.C.1
Liu, J.2
Setoguchi, S.3
Choudry, N.K.4
-
59
-
-
77950267229
-
Outcome of atrial fibrillation among patients with end-stage renal disease
-
Chou, C. Y., et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol. Dial. Transplant. 25, 1225-1230 (2010).
-
(2010)
Nephrol. Dial. Transplant.
, vol.25
, pp. 1225-1230
-
-
Chou, C.Y.1
-
60
-
-
0031801103
-
Risk of major hemorrhage for outpatients treated with warfarin
-
McMahon, D. A., Smith, D. M., Carey, M. A. & Zhou, X. H. Risk of major hemorrhage for outpatients treated with warfarin. J. Gen. Intern. Med. 13, 311-316 (1998).
-
(1998)
J. Gen. Intern. Med.
, vol.13
, pp. 311-316
-
-
McMahon, D.A.1
Smith, D.M.2
Carey, M.A.3
Zhou, X.H.4
-
61
-
-
34548047713
-
Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates
-
Elliott, M. J., Zimmerman, D. & Holden, R. M. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am. J. Kidney Dis. 50, 433-440 (2007).
-
(2007)
Am. J. Kidney Dis.
, vol.50
, pp. 433-440
-
-
Elliott, M.J.1
Zimmerman, D.2
Holden, R.M.3
-
62
-
-
38749104314
-
Major bleeding in hemodialysis patients
-
Holden, R., Harman, G. J., Wang, M., Holland, D. & Day, A. G. Major bleeding in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 105-110 (2008).
-
(2008)
Clin. J. Am. Soc. Nephrol.
, vol.3
, pp. 105-110
-
-
Holden, R.1
Harman, G.J.2
Wang, M.3
Holland, D.4
Day, A.G.5
-
63
-
-
34748904679
-
Vascular calcification in chronic kidney disease: The role of vitamin K
-
Holden, R. M. & Booth, S. L. Vascular calcification in chronic kidney disease: the role of vitamin K. Nat. Clin. Pract. Nephrol. 3, 522-523 (2007).
-
(2007)
Nat. Clin. Pract. Nephrol.
, vol.3
, pp. 522-523
-
-
Holden, R.M.1
Booth, S.L.2
-
64
-
-
34347394385
-
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
-
Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
-
(2007)
Ann. Intern. Med.
, vol.146
, pp. 857-867
-
-
Hart, R.G.1
Pearce, L.A.2
Aguilar, M.I.3
-
65
-
-
23844465424
-
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients
-
K/DOQI Workgroup
-
K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 45, S1-S153 (2005).
-
(2005)
Am. J. Kidney Dis.
, vol.45
-
-
-
66
-
-
65349189718
-
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients
-
Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J. Am. Soc. Nephrol. 20, 872-881 (2009).
-
(2009)
J. Am. Soc. Nephrol.
, vol.20
, pp. 872-881
-
-
Chan, K.E.1
Lazarus, J.M.2
Thadhani, R.3
Hakim, R.M.4
-
67
-
-
78649336758
-
Warfarin in haemodialysis patients with atrial fibrillation: What benefit?
-
Yang, F., Chou, D., Schweitzer, P. & Hanon, S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 12, 1666-1672 (2010).
-
(2010)
Europace
, vol.12
, pp. 1666-1672
-
-
Yang, F.1
Chou, D.2
Schweitzer, P.3
Hanon, S.4
-
68
-
-
79952662118
-
Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk
-
Marinigh, R., Lane, D. A. & Lip, G. Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am. Coll. Cardiol. 57, 1339-1348 (2011).
-
(2011)
J. Am. Coll. Cardiol.
, vol.57
, pp. 1339-1348
-
-
Marinigh, R.1
Lane, D.A.2
Lip, G.Y.3
-
69
-
-
80052296951
-
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
-
Herzog, C. A., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 80, 572-586 (2011).
-
(2011)
Kidney Int
, vol.80
, pp. 572-586
-
-
Herzog, C.A.1
-
71
-
-
65649142017
-
For the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate
-
Levey, A. S., et al. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009).
-
(2009)
Ann. Intern. Med.
, vol.150
, pp. 604-612
-
-
Levey, A.S.1
-
72
-
-
84855854046
-
Chronic kidney disease
-
Levey, A. S. & Coresh, J. Chronic kidney disease. Lancet 379, 165-180 (2012).
-
(2012)
Lancet
, vol.379
, pp. 165-180
-
-
Levey, A.S.1
Coresh, J.2
-
73
-
-
33744958852
-
Assessing kidney function - Measured and estimated glomerular filtration rate
-
Stevens, L. A., Coresh, J., Greene, T. & Levey, A. S. Assessing kidney function - measured and estimated glomerular filtration rate. N. Engl. J. Med. 354, 2473-2483 (2006).
-
(2006)
N. Engl. J. Med.
, vol.354
, pp. 2473-2483
-
-
Stevens, L.A.1
Coresh, J.2
Greene, T.3
Levey, A.S.4
-
74
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
-
Modification of Diet in Renal Disease Study Group
-
Levey, A. S., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461-470 (1999).
-
(1999)
Ann. Intern. Med.
, vol.130
, pp. 461-470
-
-
Levey, A.S.1
-
75
-
-
0036234755
-
Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate
-
Coresh, J., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am. J. Kidney Dis. 39, 920-929 (2002).
-
(2002)
Am. J. Kidney Dis.
, vol.39
, pp. 920-929
-
-
Coresh, J.1
|